Zelira Therapeutics Ltd has released a press release.
Zelira receives $1.2 million cash R&D Tax Incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
In the deck
Story so far
Earlier from Zelira Therapeutics
- Partial Receipt Of Zeliras EDCDM Technology License Fee
- Zelira expands into NZ via exclusive distribution agreement
- ZLD Supports Levins Chronic Pain Trial Ethics Approval
- Zelira Develops Technology and Signs New Licensing Deal
- September 2021 Quarterly Activities Report
Later from Zelira Therapeutics
- December 2021 Quarterly Activities Report
- Appendix 4D & FY22 Interim Financial Report
- Zelira Therapeutics Ltd to acquire Health House
- ZLD: Zelira to acquire Health House International Limited
- March 2022 Quarterly Activities Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics